Core Viewpoint - The company has received acceptance for the New Drug Application (NDA) of its investigational drug, TY-9591, by the National Medical Products Administration (NMPA) in China, indicating a significant step towards potential market approval for treating advanced non-small cell lung cancer (NSCLC) with specific genetic mutations [1][2]. Group 1: Drug Development and Clinical Trials - TY-9591 is a deuterated derivative of Osimertinib, demonstrating high bioavailability and effective brain penetration [1]. - The NDA application targets adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions (19DEL) or exon 21 (L858R) mutations, particularly those with CNS metastases [1]. - Phase I (TYKM1601101) and Phase II (TYKM1601201) clinical trial data indicate excellent intracranial and overall response rates in NSCLC patients with brain metastases, showcasing significant clinical benefits and addressing unmet medical needs [1]. - Key Phase II clinical trial data (TYKM1601202) further confirm superior efficacy compared to Osimertinib, particularly in terms of intracranial response rates and overall clinical benefits [1]. Group 2: Clinical Value and Advantages - TY-9591 exhibits enhanced clinical value and advantages over Osimertinib in terms of chemical structure, pharmacological action, clinical efficacy, safety, and resistance mechanism analysis [2]. - The drug is expected to significantly improve disease prognosis for patients with EGFR mutation lung cancer and brain metastases [2].
同源康医药-B(02410.HK)：甲磺酸艾多替尼片(TY-9591片)新药上市申请获受理